Hedia Appoints Rasmus Kofoed as New Chief Executive Officer
In an important leadership transition within the Danish diabetes-technology sector, Hedia has announced the appointment of Rasmus Kofoed as its new Chief Executive Officer (CEO), effective December 1, 2025. Kofoed will succeed Lars Christian Lund, who has played a pivotal role during his two years at the helm and will be transitioning to a Group CEO position at a different international organization.
Leadership Change and Strategic Vision
Carl Bilbo, the Chairman of the Board for Hedia, expressed gratitude towards Lars Christian Lund for his invaluable contributions. Under Lund's guidance, Hedia has transformed from a nascent start-up into a refined scale-up, gaining significant regulatory approvals and laying a solid foundation for future growth. Bilbo stated: "Lars has been instrumental in fortifying the organization and enabling key advancements for our global expansion. We thank him for his strong dedication and commitment to Hedia's mission." With Kofoed stepping into the role, Hedia anticipates a vigorous continuation of its strategic ambitions.
Rasmus Kofoed's Experience
Rasmus Kofoed brings a wealth of experience from the life sciences and medtech industries. His career highlights include prominent leadership positions at renowned companies such as Novo Nordisk, Abbott, Roche, and Medtronic, culminating in a successful tenure as the CEO of ChemoMetec. His extensive background provides a robust framework of knowledge and expertise in commercial strategy, growth paradigms, and international market extensions.
Ambitions for the Company
Upon his appointment, Kofoed articulated his enthusiasm for leading Hedia. "I see enormous potential in Hedia. The company uniquely combines clinical insights with innovative technology to create substantial value for individuals living with diabetes," he mentioned. He looks forward to collaborating with the talented team at Hedia to enhance market reach, solidify partnerships, and propel the company towards becoming a premier entity in the field of digital diabetes care.
Hedia's Commitment to Growth
This leadership transition marks a significant milestone in Hedia's growth trajectory, as it reaffirms their dedication to expanding their international presence and fostering meaningful commercial relationships. The company is committed to enhancing its digital solutions which empower users to better manage their health and improve their quality of life through data analytics, artificial intelligence, and intuitive app interfaces.
The Future of Digital Diabetes Care
As Hedia embraces this pivotal juncture, the integration of innovation with patient-centered care remains at the forefront of their mission. The company continues to explore new avenues to empower individuals managing insulin-dependent diabetes through advanced technological solutions and continuous improvement of their product offerings.
Frequently Asked Questions
Who is the new CEO of Hedia?
Rasmus Kofoed has been appointed as the new CEO, effective December 1, 2025.
What position did Lars Christian Lund hold at Hedia?
Lars Christian Lund served as the CEO of Hedia before his transition to a Group CEO role in another company.
What is Hedia's primary focus?
Hedia focuses on developing digital solutions that support people with insulin-dependent diabetes in managing their treatment effectively.
What are Rasmus Kofoed's main experiences?
He brings extensive leadership experience from companies like Novo Nordisk, Abbott, Roche, and Medtronic, along with his role as CEO of ChemoMetec.
What does Hedia aim to achieve with this leadership transition?
The aim is to accelerate growth, enhance international partnerships, and solidify Hedia's standing as a leader in digital diabetes management.
